En | De
Sie sind hier: Urologie-Nephrologie » Tumoren/BPH 20. Oktober 2021
Erweiterte Suche
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 7366  vorhergehende Seite nächste Seite
   Artikel 1 - 20 / 147319  
[Rational follow-up of non-muscle invasive bladder cancer].
Urologe A
von Landenberg N, Benderska-Söder N, Bismarck E, Kernig K, Erne E, Goebell PJ, Schmitz-Dräger BJ.
PMID: 34652477 [PubMed - as supplied by publisher]

[Prophylaxis of recurrence in low-to-intermediate risk non-muscle invasive bladder cancer (NMIBC)].
Urologe A
Gakis G.
PMID: 34652476 [PubMed - as supplied by publisher]

Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Clin Exp Metastasis
Pezzulla D, Macchia G, Cilla S, Buwenge M, Ferro M, Bonome P, Romano C, Zamagni A, Valentini V, Morganti AG, Deodato F.
PMID: 34651242 [PubMed - as supplied by publisher]

Nanoparticle Delivery in Prostate Tumors Implanted in Mice Facilitated by Either Local or Whole-Body Heating.
Fluids (Basel)
Gu Q, Dockery L, Daniel MC, Bieberich CJ, Ma R, Zhu L.
PMID: 34651038 [PubMed]

Biomarkers in Bladder Cancer Surveillance.
Front Surg
Sugeeta SS, Sharma A, Ng K, Nayak A, Vasdev N.
PMID: 34651010 [PubMed]

Clinical effect of robot-assisted radical cystectomy in bladder cancer.
Am J Transl Res
Lin Y, Zhang Y, Luo L, Zhang X.
PMID: 34650725 [PubMed]

Ranitidine and risk of bladder and kidney cancer: a population based cohort study.
Cancer Epidemiol Biomarkers Prev
Nørgaard M, Andersen IT, Heide-Jørgensen U, Erichsen R, Rees JR, Karagas MR, Sorensen HT.
PMID: 34649959 [PubMed - as supplied by publisher]

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
J Nucl Med
Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter R, Calais J.
PMID: 34649942 [PubMed - as supplied by publisher]

Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.
Urol Oncol
Hurle R, Guazzoni G, Colombo P, Santoro A, De Cobelli O, Trapani ED, Nohales G, Carlos L, Duran-Merino R, Lazzeri M.
PMID: 34649772 [PubMed - as supplied by publisher]

A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Biomed Pharmacother
Zhuang E, Uchio E, Lilly M, Zi X, Fruehauf JP.
PMID: 34649352 [PubMed - in process]

68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study.
Transl Oncol
Martinez J, Subramanian K, Margolis D, O'Dwyer E, Osborne J, Jhanwar Y, Nagar H, Williams N, RoyChoudhury A, Madera G, Babich J, Castellanos SH.
PMID: 34649151 [PubMed - as supplied by publisher]

A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Int J Cancer
Payne H, Robinson A, Rappe B, Hilman S, De Giorgi U, Joniau S, Bordonaro R, Mallick S, Dourthe LM, Flores MM, Gumà J, Baron B, Duran A, Pranzo A, Serikoff A, Mott D, Herdman M, Pavesi M, De Santis M.
PMID: 34648657 [PubMed - as supplied by publisher]

Tumor necrosis factor alfa (TNFα) and alfa-Klotho (αKL) in children and adolescents with chronic kidney disease (CKD).
Endokrynol Pol
Gamrot Z, Adamczyk P, , Roszkowska-Bjanid D, Gamrot J, Szczepanska M.
PMID: 34647605 [PubMed - as supplied by publisher]

Application of Organoid Models in Prostate Cancer Research.
Front Oncol
Zhou L, Zhang C, Zhang Y, Shi C.
PMID: 34646778 [PubMed]

Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Pathol Oncol Res
Zhang C, Qian J, Wu Y, Zhu Z, Yu W, Gong Y, Li X, He Z, Zhou L.
PMID: 34646089 [PubMed - in process]

Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer.
Clin Med Insights Oncol
Zhao YX, Yao GL, Sun J, Wang XL, Wang Y, Cai QQ, Kang HL, Gu LP, Yu JS, Li WM, Zhang B, Wang J, Mei JJ, Jiang Y.
PMID: 34646064 [PubMed]

Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model.
Sci Rep
Masato M, Miyata Y, Kurata H, Ito H, Mitsunari K, Asai A, Nakamura Y, Araki K, Mukae Y, Matsuda T, Harada J, Matsuo T, Ohba K, Sakai H.
PMID: 34645904 [PubMed - in process]

Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls.
Sci Rep
Wolrab D, Jirásko R, Peterka O, Idkowiak J, Chocholou, Va, Ho, Brabcová I, Vrána D, , Melichar B, Hol.
PMID: 34645896 [PubMed - in process]

Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis.
Cancer Res Treat
Suh J, Han D, Ku JH, Kim HH, Kwak C, Jeong CW.
PMID: 34645132 [PubMed - as supplied by publisher]

PSA density of the lesion: a mathematical formula that uses clinical and pathological data to predict biochemical recurrence in prostate cancer patients.
Rev Col Bras Cir
Junqueira PHR, Santos GAD, Xavier M, Romão P, Reis S, Srougi M, Nahas WC, Passerotti CC.
PMID: 34644741 [PubMed - indexed for MEDLINE]

   Artikel 1 - 20 / 147319    Seite 1 von 7366  vorhergehende Seite nächste Seite

Rect Bottom
Adserver Footer





Haben Sie Ihr Passwort vergessen?


Neu bei My Medline?

Melden Sie sich bei My Medline an!


Mehr über My Medline erfahren

mehr >>


Sky right 1